ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-


Redesigning Strategies WITH the National Pharmaceutical Pricing Authority (NPPA) finally setting up shop, it is not surprising that the first major issue it has had to consider is the five-point charter of the Organisation of Pharmaceutical Producers of India, comprising overwhelmingly MNCs and their subsidiaries, seeking a review of pricing policy. The demands are that (I) prices should be based on actual and not normative costs, (2) inflationary increases in input costs must be covered, (3) costs of utilities as fixed by the government must not be converted into cheaper prices and (4) the pricing formula should reflect the value of medicines.

To read the full text Login

Get instant access

New 3 Month Subscription
to Digital Archives at

₹826for India

$50for overseas users


(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top